tiprankstipranks
Trending News
More News >
HOYA CORPORATION (HOCPY)
OTHER OTC:HOCPY

HOYA (HOCPY) AI Stock Analysis

Compare
28 Followers

Top Page

HO

HOYA

(OTC:HOCPY)

73Outperform
HOYA's strong financial performance is a major strength, supported by consistent revenue growth, solid profit margins, and efficient management. However, technical analysis indicates a bearish trend, and the high P/E ratio suggests potential overvaluation. The low dividend yield also limits appeal for income investors.

HOYA (HOCPY) vs. S&P 500 (SPY)

HOYA Business Overview & Revenue Model

Company DescriptionHOYA Corporation operates as a med-tech company, and a supplier of high-tech and medical products worldwide. The company offers life care products, including eyeglass and contact lenses; medical endoscopes; intraocular lenses; laparoscopic surgical instruments; automatic endoscope cleaning equipment; and medical related products, such as prosthetic ceramic fillers and metallic implants. It also operates Eyecity, a specialty retailer of contact lenses. In addition, the company provides information technology products, such as mask blanks and photomasks for manufacturing semiconductor chips; photomasks for liquid crystal display panels; glass disks for hard disk drives; and imaging products that include optical glasses/optical lenses, colored glass filters, and laser equipment/UV light resources. Further, it offers ReadSpeaker, a speech synthesis software; and cloud services comprising Kinnosuke that is a time and attendance management service, and Yonosuke, an electronic payslip service. HOYA Corporation was founded in 1941 and is headquartered in Tokyo, Japan.
How the Company Makes MoneyHOYA Corporation generates revenue through its two main business segments: Life Care and Information Technology. In the Life Care segment, the company earns money from the sale of eyeglass lenses, which are distributed globally, and medical products like endoscopes and intraocular lenses, catering to the healthcare industry. The Information Technology segment contributes to revenue through the production and sale of photomasks used in semiconductor manufacturing, glass substrates for hard disk drives, and other optical components. HOYA's business model is supported by strategic partnerships with healthcare providers and technology companies, along with continuous investment in research and development to innovate and meet market demands. The company's diversified product portfolio and global reach are significant factors in its earnings.

HOYA Financial Statement Overview

Summary
HOYA demonstrates robust financial health across key financial statements. The company shows consistent revenue and profit growth, efficient operational management, and strong cash flow generation. Its balance sheet is solid with minimal debt, high equity, and strong returns on equity. Overall, HOYA is well-positioned in its industry with impressive financial metrics.
Income Statement
87
Very Positive
HOYA exhibits strong income statement performance with consistently growing revenue and solid profit margins. The gross profit margin remains robust at approximately 55.3%, and net profit margin is healthy at 23.8% for the latest annual period. Revenue has shown a positive growth trend with a 3.9% increase from the previous year. EBIT and EBITDA margins are strong at 46.4% and 37.5% respectively, indicating efficient operational management.
Balance Sheet
85
Very Positive
HOYA's balance sheet reflects a stable financial position. The debt-to-equity ratio is very low at 0.03, indicating minimal reliance on debt financing. Return on equity is impressive at 18.8%, showcasing effective use of shareholder funds. The equity ratio stands at 80.4%, highlighting a strong capital structure with substantial equity backing.
Cash Flow
82
Very Positive
The cash flow statement shows strong cash generation abilities. Free cash flow has grown by 7.9% over the last year, and the operating cash flow to net income ratio is 1.23, indicating healthy cash conversion from profits. The free cash flow to net income ratio is also favorable at 1.00, underscoring the company's ability to generate cash relative to its net earnings.
Breakdown
TTMMar 2024Mar 2023Mar 2022Mar 2021Mar 2020
Income StatementTotal Revenue
807.35B762.61B734.10B670.33B558.26B582.47B
Gross Profit
616.72B421.69B631.86B567.28B474.98B488.09B
EBIT
264.12B353.80B210.17B200.94B163.93B147.72B
EBITDA
267.89B285.70B259.78B243.96B200.27B182.09B
Net Income Common Stockholders
190.14B181.38B168.64B164.51B125.45B114.41B
Balance SheetCash, Cash Equivalents and Short-Term Investments
173.31B525.16B426.27B426.63B338.79B319.29B
Total Assets
549.74B1.20T1.03T992.84B853.29B811.01B
Total Debt
105.42B29.24B24.58B21.60B20.75B21.97B
Net Debt
-67.89B-495.92B-381.31B-397.80B-314.15B-296.02B
Total Liabilities
198.26B241.36B213.72B203.78B180.88B181.74B
Stockholders Equity
350.28B967.76B818.32B803.85B688.00B645.04B
Cash FlowFree Cash Flow
175.10B181.73B168.36B161.18B120.57B118.19B
Operating Cash Flow
220.32B222.80B201.83B190.06B151.81B163.37B
Investing Cash Flow
-32.13B-35.81B-47.50B-29.30B-29.79B-47.38B
Financing Cash Flow
-135.03B-110.89B-194.59B-106.72B-115.67B-85.47B

HOYA Technical Analysis

Technical Analysis Sentiment
Negative
Last Price108.56
Price Trends
50DMA
116.29
Negative
100DMA
123.36
Negative
200DMA
128.12
Negative
Market Momentum
MACD
-3.09
Negative
RSI
46.20
Neutral
STOCH
88.65
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HOCPY, the sentiment is Negative. The current price of 108.56 is below the 20-day moving average (MA) of 109.91, below the 50-day MA of 116.29, and below the 200-day MA of 128.12, indicating a bearish trend. The MACD of -3.09 indicates Negative momentum. The RSI at 46.20 is Neutral, neither overbought nor oversold. The STOCH value of 88.65 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HOCPY.

HOYA Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
RMRMD
77
Outperform
$31.27B25.1525.65%0.97%9.38%40.38%
COCOO
75
Outperform
$15.90B38.455.25%7.15%41.96%
73
Outperform
$36.05B26.4421.60%0.48%4.38%16.89%
WSWST
64
Neutral
$14.60B30.2017.71%0.41%-1.93%-15.47%
61
Neutral
$4.26B-4.76%15.56%-21.60%
54
Neutral
$833.11M55.81-5.16%-2.64%-193.31%
51
Neutral
$5.19B3.12-41.08%2.95%17.98%2.02%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HOCPY
HOYA
108.56
-4.80
-4.23%
COO
Cooper Co
79.51
-10.53
-11.69%
RMD
Resmed
212.91
34.18
19.12%
STAA
Staar Surgical
16.89
-29.66
-63.72%
WST
West Pharmaceutical Services
201.90
-172.52
-46.08%
BLCO
Bausch + Lomb Corporation
12.06
-2.58
-17.62%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.